News & articles

What’s Next? At the end of a productive meeting, day, or week, I’m always asking myself, “what’s next.” Next on my calendar, next on my list, next on the agenda. Last year, I recognized that to get to what’s next as a foundation, I first had to learn, listen, and prepare. I learned about the… Read More »New Year’s Note from CEO, Kapila Viges

In an article in Targeted Oncology entitled, “The Expanding Role of Interferons in Myeloproliferative Neoplasms,” Dr. Richard Silver, director emeritus of the Silver MPN Center at Weill Cornell Medicine, discussed the importance of our three-year global Interferon Initiative to shed light on key questions such as which patients are likely to benefit from recombinant interferon alpha and why resistance to it may develop over… Read More »Targeted Oncology Highlights Global Interferon Initiative

Earlier this month, we joined our global partners as part of the 6th International MPN Horizons Conference, convening MPN advocates from 33 countries to share the latest research, care standards, and current therapies.  Amongst the rich medical and advocacy content presented, Kapila Viges of MPNRF co-chaired two medical sessions. The first highlighted genetic testing, disease progression,… Read More »Global Research Impacts Patients Around the World

When ruxolitinib (Jakafi®) was approved by the U.S. Food and Drug Administration (FDA) to treat myelofibrosis (MF) ten years ago, it was celebrated as the first treatment specifically for an MPN. Three years later, it was approved to treat polycythemia vera (PV). The landscape for patients is much different now than when ruxolitinib was initially… Read More »The Changing Landscape for Patients

Chicago, IL, November 1, 2021 (Newswire) – In real world usage and in clinical trials, interferon (IFN), in a variety of forms, has shown high rates of hematologic and molecular responses in most patients with polycythemia vera (PV) and essential thrombocythemia (ET), and some patients in the early phase of primary myelofibrosis (PMF), together a… Read More »3-Year Global MPN Interferon Initiative 

As we all slowly come back to cautious travel and meeting colleagues in person, Lindsey Whyte and Kapila Viges represented the MPN Research Foundation (MPNRF) in New York for the 20th International Congress on Myeloproliferative Neoplasms. The signature event for gathering MPN clinicians, still chaired by Dr. Dick Silver and Dr. Jerry Spivak, was in… Read More »20th International Congress on Myeloproliferative Neoplasms

In our August Digest, we asked readers for one piece of advice they would give someone who was recently diagnosed with ET, PV or MF. We are grateful to everyone who shared their perspectives, some of which are highlighted below.  JD of Denver, Colorado: Reach out to others with PV to understand the disease better and how you can thrive and live… Read More »We Asked, You Answered: Part Two 

The MPN Research Foundation (MPNRF) continued its commitment to furthering our understanding of disease progression by holding its 2nd MPN Progression Research Network Summit on October 15. We convened over 60 representatives from the academic medical community and biopharmaceutical companies, among other key stakeholders, for a three-hour virtual meeting to discuss the state of the… Read More »2021 MPN Progression Research Network Summit

We’re pleased to share the following presentation on the outlook of MPNs by Dr. Ruben Mesa, executive director, at UT Health San Antonio MD Anderson Cancer Center. https://www.youtube.com/watch?v=rvm5mTcSCfQ

In our August Digest, we asked readers what was one thing they wished their clinician had told them at the start of their MPN journey. We appreciate each person who wrote in to share their perspectives, some of which are below. Two themes that were raised by multiple respondents were the importance of seeing an… Read More »We Asked, You Answered: Part One